Clinical Evaluation of the VIPUN Balloon Catheter 0.1

NCT ID: NCT03239821

Last Updated: 2018-05-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-25

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of this investigation is to assess the safety, feasibility and performance of the VIPUN Balloon Catheter 0.1 in the assessment of gastric motility. The investigation will also assess whether the inflation of the VIPUN Balloon Catheter can stimulate gastric motility and emptying. Furthermore, this investigation will examine whether gastric motility and emptying as measured in this study are correlated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Motility Disorder Gastric Emptying

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

A single-blinded, monocenter, randomized crossover investigation in healthy volunteers.
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo - deflated balloon

Group Type SHAM_COMPARATOR

VIPUN Balloon Catheter 0.1 deflated

Intervention Type DEVICE

deflation balloon

Placebo

Intervention Type DRUG

Sirupus Simplex

Placebo - inflated balloon

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Sirupus Simplex

VIPUN Balloon Catheter 0.1 inflated

Intervention Type DEVICE

VIPUN Balloon Catheter 0.1 inflated

Codeine - delfated balloon

Group Type ACTIVE_COMPARATOR

VIPUN Balloon Catheter 0.1 deflated

Intervention Type DEVICE

deflation balloon

Codeine Phosphate

Intervention Type DRUG

58.8 mg codeïne phosphate

Codeine - inflated balloon

Group Type ACTIVE_COMPARATOR

Codeine Phosphate

Intervention Type DRUG

58.8 mg codeïne phosphate

VIPUN Balloon Catheter 0.1 inflated

Intervention Type DEVICE

VIPUN Balloon Catheter 0.1 inflated

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VIPUN Balloon Catheter 0.1 deflated

deflation balloon

Intervention Type DEVICE

Codeine Phosphate

58.8 mg codeïne phosphate

Intervention Type DRUG

Placebo

Sirupus Simplex

Intervention Type DRUG

VIPUN Balloon Catheter 0.1 inflated

VIPUN Balloon Catheter 0.1 inflated

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed Informed Consent
* Aged between and including 18 and 65 years
* BMI between and including 18 and 25
* Understand and able to read Dutch
* In good health on the basis of medical history
* Able to return home without driving a vehicle on visit days 1-4
* Will not operate machines on the same day of treatment (visits 1-4)
* Females subjects of childbearing potential are willing to use adequate contraception
* Refrains from herbal, vitamin and other dietary supplements on the day of the visits

Exclusion Criteria

* Dyspeptic symptoms (assessed with PAGI-SYM questionnaire)
* Using any medication that might affect gastric function or visceral sensitivity
* Known / suspected current use of illicit drugs
* Known psychiatric or neurological illness
* Any gastrointestinal surgery that could influence normal gastric function in the opinion of the investigator


* History of heart or vascular diseases like irregular heartbeats, angina or heart attack
* Nasopharyngeal, upper GI or esophageal surgery in the last 30 days
* Suspected basal skull fracture or severe maxillofacial trauma
* History of thermal or chemical injury to upper respiratory tract or esophagus
* Current esophageal or nasopharyngeal obstruction
* Known coagulopathy
* Known esophageal varices


* History of opioid dependency
* Known severely decreased kidney or liver function
* Pregnant or breastfeeding women (pregnancy test will be performed on females with childbearing potential)
* Known severe lung disease (e.g. asthma or emphysema)
* Have known side-effects/allergic reactions when taking codeine/morphine
* Known diabetic, fructose intolerance or malabsorption of glucose or galactose or sucrose-isomalase insufficiency.


• Known diabetic (saccharose), intolerance to or malabsorption of propylene glycol and methyl- and propylparahydroxybenzoate


• Have a known allergy or intolerance to cow milk, soy, saccharose or any other ingredient of Fortimel Energy
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UZ Leuven Gasthuisberg

Leuven, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S60320

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MENDD Tolerance Assessment Study
NCT06185088 TERMINATED NA
Central Obesity in Cases of OAB
NCT03750604 COMPLETED NA
INGEST I Pilot Study
NCT03885310 UNKNOWN NA